pressreleases

HANetf’s Medicinal Cannabis Fund (CBDX) Has Been Passported for Distribution in the Netherlands and Finland | CBDX

• The ETF was initially listed in Frankfurt (XETRA) and has since also been listed on the London Stock Exchange. TER 80bps
• This is the first and still the only ETF available in Europe as a UCITS that tracks medical cannabis

London, 14, February, 2020 - HANetf, Europe’s first ‘white label’ ETF issuer, has registered its landmark medical cannabis ETF for sale in the Netherlands and Finland. CBDX – The Medical Cannabis and Wellness UCITS ETF - was launched in January 2020 on XETRA and the London Stock Exchange with Purpose Investments as sponsor.

CBDX provides investors with the opportunity to gain exposure to a basket of carefully vetted companies that have high exposure to the medicinal cannabis, hemp and cannabinoids (CBD) industry. It is the only UCITS ETF which is providing this level of targeted exposure.

The fund tracks a rules-based Medical Cannabis and Wellness Equity Index from Solactive, consisting of publicly listed companies conducting legal business activities in the medical cannabis, hemp and CBD industries. The methodology uses a rigorous and multi-tiered screening process to identify and exclude companies that are involved in the adult-use Cannabis market.

CBDX is constantly monitored to ensure that it remains focused exclusively on stocks that are dedicated to the medical cannabis market. Companies that have retail cannabis exposure are screened out.

The sponsor of CBDX is Purpose Investments of Canada. Purpose is a highly innovative fund management business with over US$8 billion in assets under management (as of January 2020). In 2017, Purpose Investments launched a cannabis fund in Canada (the Purpose Marijuana Opportunities Fund), and have a have a deep understanding of this exciting, high growth industry sector.

Nawan Butt, Portfolio Manager at Purpose Investments, commented: “The launch of CBDX in the UK and Germany comes at a time when the sell-off in cannabis stocks has created new value and a new entry point for investors interested in this sector. Medicinal stocks in this sector are again showing value against long term growth targets. We expect to see further deregulation of medical cannabis products and additional take up within the healthcare sector in the near future, which will drive prices.”

Ignatius Faisal, Director of Product Management at HANetf, added: “While the North American ETF market is well-served with products that track cannabis indexes, this is the first and currently only UCITS ETF authorized for distribution in the European market. With the addition of the Netherlands and Finland as markets for distribution, more investors will be able to access the fast-developing medical cannabis story.”

Investors considering CBDX should be aware of the following risks and consult the KIID and Prospectus on www.hanetf.com for further information.

• The value of equities and equity-related securities can be affected by daily stock and currency market movements
• Investors' capital is fully at risk and investors may not get back the amount originally invested
• Exchange rate fluctuations could have a negative or positive effect on returns